Krystal Biotech, Inc.

{
  "main_header": {
    "sid": 1245865,
    "name": "Krystal Biotech, Inc.",
    "stock_name": "Krystal Biotech, Inc.",
    "full_name": "Krystal Biotech, Inc.",
    "name_url": "stocks-analysis/krystal-biotech-inc",
    "exchange": 1,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "281.53",
    "chg": 145.45,
    "chgp": "106.89%",
    "dir": 1,
    "prev_price": "136.08",
    "mcapval": "8,293.29",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US5011471027",
    "curr_date": "Jan 23",
    "curr_time": "",
    "bse_nse_vol": "662.62 k",
    "exc_status": "Active",
    "traded_date": "Jan 23, 2026",
    "traded_date_str": "2026 01 23",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/krystal-biotech-inc-1245865-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Krystal Biotech Adjusts Valuation Amid Strong Financial Performance and Growth Indicators",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/krystal-biotech-receives-upgrade-to-strong-buy-following-valuation-improvement-3690051",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/KrystalBiotechI_mojoScore_3690051.png",
        "date": "2025-11-11 16:37:05",
        "description": "Krystal Biotech, Inc. has recently experienced a revision in its evaluation, moving to a fair valuation grade. The company showcases strong financial metrics, including a P/E ratio of 27 and a PEG ratio of 0.25, alongside impressive returns on capital and equity, reflecting effective resource management and consistent growth."
      },
      {
        "title": "Is Krystal Biotech, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-krystal-biotech-inc-overvalued-or-undervalued-3689276",
        "imagepath": "",
        "date": "2025-11-11 11:33:51",
        "description": "As of 7 November 2025, the valuation grade for Krystal Biotech, Inc. moved from expensive to fair. This suggests that the stock is currently fairly valued. Key valuation ratios include a P/E ratio of 27, an EV to EBITDA ratio of 23.83, and a PEG ratio of 0.25, indicating a strong growth potential relative to its price.\n\nIn comparison to its peers, Krystal Biotech's P/E ratio is higher than that of Halozyme Therapeutics, Inc., which has a P/E of 15.92, and significantly above Elanco Animal Health, Inc. at 19.25. Despite this, the company has demonstrated robust performance with a year-to-date return of 27.36%, significantly outpacing the S&P 500's return of 14.40% over the same period, reinforcing the notion that the stock is positioned well in the market...."
      },
      {
        "title": "Is Krystal Biotech, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-krystal-biotech-inc-overvalued-or-undervalued-3683187",
        "imagepath": "",
        "date": "2025-11-09 11:09:12",
        "description": "As of 7 November 2025, Krystal Biotech, Inc. has moved from an expensive to a fair valuation grade. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 27, a Price to Book Value of 4.02, and an EV to EBITDA ratio of 23.83. In comparison to its peers, Krystal's P/E ratio is higher than Halozyme Therapeutics, Inc. at 15.92 and Elanco Animal Health, Inc. at 19.25, indicating a premium valuation relative to these companies.\n\nThe PEG ratio of 0.25 suggests that the stock may be undervalued in terms of its growth prospects, especially when compared to the industry average. Additionally, Krystal Biotech has delivered strong returns, outperforming the S&P 500 with a year-to-date return of 26.34% compared to the index's 14.40%. Overall, the valuation metrics and strong performance suggest that Krystal Biotech is fairly valued at this time...."
      },
      {
        "title": "Krystal Biotech Hits New 52-Week High of $212.98, Showcasing Strong Growth",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/krystal-biotech-hits-new-52-week-high-of-21298-showcasing-strong-growth-3674064",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/KrystalBiotechI_priceRelatedfactors_3674064.png",
        "date": "2025-11-05 16:51:53",
        "description": "Krystal Biotech, Inc. has achieved a new 52-week high, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. The company has a market capitalization of USD 4,203 million, a P/E ratio of 27.00, and has reported significant growth in net profit and operating cash flow over recent quarters."
      }
    ],
    "total": 21,
    "sid": "1245865",
    "stock_news_url": "https://www.marketsmojo.com/news/krystal-biotech-inc-1245865"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Krystal Biotech Adjusts Valuation Amid Strong Financial Performance and Growth Indicators

2025-11-11 16:37:05

Krystal Biotech, Inc. has recently experienced a revision in its evaluation, moving to a fair valuation grade. The company showcases strong financial metrics, including a P/E ratio of 27 and a PEG ratio of 0.25, alongside impressive returns on capital and equity, reflecting effective resource management and consistent growth.

Read full news article

Is Krystal Biotech, Inc. overvalued or undervalued?

2025-11-11 11:33:51

As of 7 November 2025, the valuation grade for Krystal Biotech, Inc. moved from expensive to fair. This suggests that the stock is currently fairly valued. Key valuation ratios include a P/E ratio of 27, an EV to EBITDA ratio of 23.83, and a PEG ratio of 0.25, indicating a strong growth potential relative to its price. In comparison to its peers, Krystal Biotech's P/E ratio is higher than that of Halozyme Therapeutics, Inc., which has a P/E of 15.92, and significantly above Elanco Animal Health, Inc. at 19.25. Despite this, the company has demonstrated robust performance with a year-to-date return of 27.36%, significantly outpacing the S&P 500's return of 14.40% over the same period, reinforcing the notion that the stock is positioned well in the market....

Read full news article

Is Krystal Biotech, Inc. overvalued or undervalued?

2025-11-09 11:09:12

As of 7 November 2025, Krystal Biotech, Inc. has moved from an expensive to a fair valuation grade. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 27, a Price to Book Value of 4.02, and an EV to EBITDA ratio of 23.83. In comparison to its peers, Krystal's P/E ratio is higher than Halozyme Therapeutics, Inc. at 15.92 and Elanco Animal Health, Inc. at 19.25, indicating a premium valuation relative to these companies. The PEG ratio of 0.25 suggests that the stock may be undervalued in terms of its growth prospects, especially when compared to the industry average. Additionally, Krystal Biotech has delivered strong returns, outperforming the S&P 500 with a year-to-date return of 26.34% compared to the index's 14.40%. Overall, the valuation metrics and strong performance suggest that Krystal Biotech is fairly valued at this time....

Read full news article

Krystal Biotech Hits New 52-Week High of $212.98, Showcasing Strong Growth

2025-11-05 16:51:53

Krystal Biotech, Inc. has achieved a new 52-week high, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. The company has a market capitalization of USD 4,203 million, a P/E ratio of 27.00, and has reported significant growth in net profit and operating cash flow over recent quarters.

Read full news article

View All News